anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A remote expert assists a local operator of a medical imaging device during a medical imaging examination. A user interface (UI) is provided on an assistor electronic device operable by the remote expert. The UI displays controller video output by an electronic controller of the medical imaging device. Graphical annotations for updating the controller video are received via at least one user input device of the assistor electronic device. The controller video overlaid with the graphical annotations is displayed on a controller display of the medical imaging device. In one approach, this entails splitting the controller video into a plurality of feeds, transmitting one of the feeds to the assistor electronic device, and transmitting another of the feeds to a screen overlay processor that also receives the graphical annotations from the assistor electronic device and that generates the controller video overlaid with the graphical annotations.
Example embodiments provide real time quality monitoring of a magnetic resonance imaging (MRI) scan. Data associated with an MRI scan of a particular patient is received. The data is sequential MRI data associated with various times. A rate of change of the sequential data is determined with reference to the various times. It is determined whether the rate of change of the sequential data meets a first configurable threshold. It is determined whether the rate of change of the sequential data meets a second configurable threshold. The sequential data is classified based on whether the rate of change of the sequential data meets the first and second configurable thresholds.
Patients will download the "Breathe2Relax" app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention.
PURPOSE:To obtain the subject cosmetic useful for treatment after shampooing by blending an amphoteric surfactant having high safety with a cationic polymer, adding an oil agent and an organic acid or an inorganic acid and controlling pH to <=5. CONSTITUTION:An amphoteric surfactant (especially preferably amidoamino acid type amphoteric surfactant or imidazoline type amphoteric surfactant) is combined with a cationic polymer (e.g. cationic cellulose derivative or quaternized polyvinyl pyrrolidone derivative), an oil agent (e.g. dimethylpolysiloxane or dimethylcyclopolysiloxane), a germicide (e.g. piclotolamin or triclosan) and an organic acid or an inorganic acid and the whole composition is adjusted to pH <=5 to give an emulsion cosmetic for scalp and hair. This cosmetic provides hair with excellent smoothness and flexibility, splendidly keeps scalp healthy, has low irritation and good emulsion stability.
A data communication system is provided which permits collaboration between distributed clinicians regarding distributed or remote implantable medical devices (IMDs). A central computing resource capable of storing and distributing patient device and clinician location and contact data is provided, as well as a network providing communication with the computing resource. A deployed IMD may be polled by an interface device external to the host patient, and data may be transmitted to the interface device by wireless communication. This data may be transmitted to a central computer for storage and distribution. The data may be distributed to various clinicians in communication with the central computer. These clinicians may use this information, either directly or indirectly, to contact remote clinicians and medical devices in communication with the network.
The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and insulin release, respectively. The methods and compositions are directed toward increasing the activity of scavenger cells within the body at recognizing and removing amyloid deposits from affected tissues and organs. Scavenger cells may be targeted to amyloid deposits by means of spontaneously-occurring chemical modifications called advanced glycosylation endproducts (AGEs). Compositions are described which increase scavenger cell activity towards AGE-modified amyloid. Amyloid removal may also be enhanced by increasing AGE levels in amyloid deposits within the body by administering AGE-modified amyloid targeting agents, which after becoming situated at sites containing amyloid, subsequently attract scavenger cells to degrade attendant amyloid. These methods and associated compositions result in a decrease in the extent of amyloid deposits in tissues, reducing the attendant pathology.
BACKGROUND: Mycoplasma pneumoniae (MP) infection serves as a substantial cofactor in Kawasaki disease (KD) among patients. Although the dominant issue triggering KD has recently focused on MP infection, the complete demonstration of the relationship between MP infection and KD remains elusive. This study endeavors to scrutinize and compare the clinical manifestations and cardiac involvement between MP-triggered KD and non-infection-associated KD.
METHOD: This retrospective study (2023-039, approved by the Institutional Review Board of West China Second University Hospital of Sichuan University) encompassed 247 consecutive patients diagnosed with KD between June 2017 and December 2022. Patients were categorized into two groups: the MP group (n = 38) and the non-MP group (n = 209). Univariable analysis was utilized to discern differences in clinical features, severity of inflammation, and initial or persistent cardiac complications between the two groups.
RESULTS: The MP group exhibited a more intricate clinical profile compared with the non-MP group, characterized by prolonged hospital stays, a higher incidence of incomplete KD, and elevated comorbidities. In addition, MP infection correlated with severe hematological disorders, coagulation dysfunction, and myocardial injuries. Our findings revealed that MP infection led to prolonged inflammation after initial treatment with intravenous immunoglobulin. Although initial cardiac assessments failed to discern disparities between the two groups, MP infection notably exacerbated coronary artery aneurysms (CAAs), resulting in sustained dilation.
CONCLUSIONS: Recognizing MP infection as a significant infectious factor associated with KD is imperative. In patients with KD, MP infection significantly prolongs inflammation and causes hematological disturbances during the initial treatment phase. Moreover, the presence of MP infection exacerbates the progression of CAAs and myocardial injuries during the subacute phase of KD, consequently contributing to the persistence of CAAs.
OBJECTIVE: Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control.
DESIGN: We conducted shotgun metagenomic microbiome and resistome analysis on serial oropharyngeal and faecal samples collected from critically ill, mechanically ventilated patients in a pilot multicentre cluster randomised trial of SDD. The microbiome and AMR profiles were compared for longitudinal and intergroup changes. Of consented patients, faecal microbiome baseline samples were obtained in 89 critically ill children. Additionally, samples collected during and after critical illness were collected in 17 children treated with SDD-enhanced infection control and 19 children who received standard care.
RESULTS: SDD affected the alpha and beta diversity of critically ill children to a greater degree than standard care. At cessation of treatment, the microbiome of SDD patients was dominated by Actinomycetota, specifically Bifidobacterium, at the end of mechanical ventilation. Altered gut microbiota was evident in a subset of SDD-treated children who returned late longitudinal samples compared with children receiving standard care. Clinically relevant AMR gene burden was unaffected by the administration of SDD-enhanced infection control compared with standard care. SDD did not affect the composition of the oral microbiome compared with standard treatment.
CONCLUSION: Short interventions of SDD caused a shift in the microbiome but not of the AMR gene pool in critically ill children at the end mechanical ventilation, compared with standard antimicrobial therapy.
High risk \[metastatic, resected, incompletely resected, or unresected disease\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
Provided is a continual drug release device that can be implanted and can be replenished with drugs, the drug release device achieving drug delivery such that the drug release rate is controllable.　This drug release device configured to be implanted in a living body allows drug replenishment in which drugs are supplied by the use of a syringe and a needle while the device remains implanted. The device has a capsule structure that includes: (i) a drug release section for releasing a drug to outside the device; (ii) a drug storage section for holding the drug; and (iii) a drug introduction section for introducing the drug to the drug storage section. The drug release section has a releasing surface having pores, and a hydrogel is kept in the drug release section. The drug storage section is adjacent to the drug release section. The drug held in the drug storage section passes through the drug release section and is released through the drug release section pores. Drugs are introduced into the drug storage section through the drug introduction section by the use of a syringe and a needle.
Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
Patients with recurrent C. difficile infections, who failed FMT. This cohort includes patients treated with a combination of bezlotoxumab (Zinplava) and 2nd FMT.
PROBLEM TO BE SOLVED: To obtain a medicine composition capable of suppressing occurrence of breast cancer in female after menopause by a specific dose, comprising raloxifene as an active ingredient. SOLUTION: Raloxifene of the formula is obtained by using benzo[b]thiophene containing a 6-hydroxyl group and 2-(4-hydroxyphenyl) group as a starting substance, protecting the hydroxyl group, acylating the 3-position and deprotecting the reaction product. A medicine composition comprising raloxifene (salt) as an active ingredient is obtained. The composition is pharmaceutically manufactured with a general excipient, diluent and carrier into tablet, capsule, suspension, powder, etc., to give the medicine composition. Raloxifene (salt) is administered in an amount of 30-150mg, preferably 50-70mg per day for >=6 months, preferably >=2 years. Oral administration is preferable as the method for administration.
NEW MATERIAL:Panaxacol[colorless granular crystal; mass spectrometry(FD- MS):m/z279(M+1); IR spectrum: table 1; UV spectrum: table II; H<1>-NMR spectrum: table III]. USE:A carcinostatic agent. PREPARATION:Root of Panax, ginseng C.A.Meyer or its callus is ground by a mixer, and extracted with a solvent such as ethyl acetate, etc., while being treated with ultrasonic wave. The extracted solution is filtered, concentrated, and the residue is subjected to silica gel chromatography. The resultant substance is successively eluted by changing a blending ratio of a mixed solvent of hexane and ethyl acetate. A fraction of hexane: ethyl acetate=2:1 which is observed to have an inhibitory action on growth of Yoshida sarcoma culture cell among elution fractions is subjected to high-speed liquid chromatography and partially collected, to give pure panaxacol. A carcinostatic agent usable for oral and parenteral administration comprising it as an active ingredient is obtained. An oral dose is 0.01-100mg/kg/day.
If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
The present invention relates to an extract of Dionaea muscipula and a composition comprising such an extract for cosmetic treatment of the skin and skin appendages such as sebaceous glands, hair and nails especially skin changes due to accelerated or chronological aging e.g. wrinkles loss of firmness and elasticity, and increased pigmentation. It also regards the use of such an extract for the preparation of a composition for cosmetic treatment. The composition may comprise further substances active against skin changes due to accelerated or chronological aging e.g. wrinkles loss of firmness and elasticity, and increased pigmentation. Especially it may contain an extract from Cymbidium erythraeum. It may also comprise bases, cosmetic pigments, UV filters and/or UV scattering agents. The scope of the invention also covers a method for cosmetic treatment of the skin, especially skin changes due to accelerated or chronological aging e.g. wrinkles loss of firmness and elasticity, and increased pigmentation wherein a persons skin is treated with a composition comprising an extract from Dionaea muscipula. Such a composition may also contain an extract from Cymbidium erythraeum.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent insecticidal/ acaricidal effectiveness by making the composition include phenoxyphenyl pyridyloxypropyl ether and difluorophenylethoxy-tertiary-butylphenyloxazoline as active ingredients. SOLUTION: This composition comprises (A) 4-phenoxyphenyl 2-(pyridyloxy) propyl ether and (B) 2-(2,6-difluorophenyl)-4-(2-ethoxy-4-tertiary-butylphenyl)-2- oxazoline as active ingredients. In the composition, the total contents of the component A and the component B is 0.01-90 wt.% and the amount of the component B is preferably 0.01-30 pts.wt. based on 1 pt.wt. of the component A. In the case of applying the composition as a controller for insect pests of agriculture and forestry, the amount of application is preferably 1-1,000 g of the total of the active ingredients based on 10 ares.
PURPOSE: Myasthenia gravis (MG) is the most common autoimmune disease that affects the neuromuscular junction and can cause weakness in various muscle groups. The most commonly affected muscles are the eye, facial, and neck flexors. Focal or dominant weakness of the triceps muscle is rare. In this case, we aimed to describe a rare form of MG consisting of selective or dominant triceps muscle weakness.
CASE REPORT: We present a 45-year-old male patient whose initial complaints were diplopia and ptosis. Acetylcholine receptor antibody was positive. After 10 years of well-being following thymectomy, bilateral triceps weakness was added to his ocular symptoms despite regular medication (pyridostigmine and prednisone). Repetitive nerve stimulation (RNS) showed decremental responses in the right triceps muscles.
CONCLUSION: It is important to recognize this type of myasthenia gravis to facilitate diagnosis and appropriate treatment and to avoid unnecessary investigations and treatments.
The following provides an exemplary method. An image is generated. Scan data generated by the sensing of a subject brain is received and a sequence of volumetric-images are accessed. For at least some of the voxels in at least some of the volumetric images, a change value is determined for the voxel by comparing the current-intensity value of the voxel to the adjacent-intensity value of the comparison voxel. For at least some of the plurality volumetric images, a first-aggregate is determined using at least a mean value of change values of the volumetric image and a second-aggregate is determined using at least a median value of change values of the volumetric image. At least one, but not all, of the volumetric images is determined as invalid as a result of the aggregates.
Aim 1: Implement a refined mental health (MH) intervention in caregivers of hospitalized children: sessions with a Behavioral Health Clinician (BHC) with more individualized support based on caregiver-child needs, instruction on caregiver-child bonding, and a streamlined handoff to a community MH provider. Follow-up outcomes include caregiver MH and caregiver-child attachment (survey) and child development (electronic health records, EHR).

Aim 2: Execute an enhanced intervention for FI. All families who screen positive for FI will still receive assistance with public benefit enrollment and access to local food pantries. Families with additional needs will receive support for 10 additional non-medical drivers of health (NMDH). Assistance will be provided by onsite Houston Food Bank (HFB) Community Referral Specialists. Follow-up outcomes include enrollment in public/community resources and food security status (survey).
A method that includes introducing a catheter assembly to an obstructed region of a blood vessel lumen and recanalizing the obstructed region with the catheter assembly is disclosed. Prior to or during recanalization, a treatment agent may be delivered through the catheter assembly to a vessel region downstream to the obstructed region. The treatment agent may have a property that will inhibit reperfusion injury. Alternatively, a medical device may be introduced to an obstructed region of a blood vessel lumen and the obstructed region recanalized with the medical device. The treatment agent may be delivered to a vessel region downstream to the obstructed region. The treatment agent may include at least one of an immunosuppresant and an antioxidant. In other methods, a delivery cannula may be introduced to an unperfused region of an occluded vessel without disrupting the occlusion and the treatment agent having a property that will inhibit reperfusion injury may be delivered to the unperfused region through the delivery cannula. After delivering the treatment agent, the occluded vessel may be recanalized by advancing an angioplasty device into the occluded vessel.
Lung diseases develop when telomeres shorten beyond a critical point. We constructed a mouse model in which the catalytic subunit of telomerase (mTert), or its catalytically inactive form (mTertCI), is expressed from the p21Cdkn1a locus. Expression of either TERT or TERTCI reduces global p21 levels in the lungs of aged mice, highlighting TERT non-canonical function. However, only TERT reduces accumulation of very short telomeres, oxidative damage, endothelial cell (ECs) senescence and senile emphysema in aged mice. Single-cell analysis of the lung reveals that p21 (and hence TERT) is expressed mainly in the capillary ECs. We report that a fraction of capillary ECs marked by CD34 and endowed with proliferative capacity declines drastically with age, and this is counteracted by TERT but not TERTCI. Consistently, only TERT counteracts decline of capillary density. Natural aging effects are confirmed using the experimental model of emphysema induced by VEGFR2 inhibition and chronic hypoxia. We conclude that catalytically active TERT prevents exhaustion of the putative CD34 + EC progenitors with age, thus protecting against capillary vessel loss and pulmonary emphysema.
An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.
The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I,where the variables R1-R9 and X are defined herein and at least one surface stabilizer. The surface stabilizer can be a polymeric surface stabilizer such as hydroxyethyl starch, dextran, or povidone. The injectable neurosteroid nanoparticle formulation can be an intravenous formulation. The disclosure also provides a lyophilized powder of the injectable neurosteroid nanoparticle formulation that can be reconstituted in an aqueous solution prior to administration. The disclosure provides injectable neurosteroid nanoparticle formulations and dry powders of such formulations that have been sterilized by ebeam irradiation. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable neurosteroid nanoparticle formulation. The disclosure also provides combination methods in which the injectable neurosteroid nanoparticle formulation is a first active agent that is administered in combination with at least one additional active agent.
EA was given every day three days before surgery, 30 minutes before induction of anesthesia + the whole course of surgery, and every 12 hours from the first day after surgery, each treatment was performed for 30 minutes until 48 hours after surgery. During the operation, only dexmedetomidine was used to make BIS\<80.
FIELD: medicine, oncology. SUBSTANCE: product: conjugates with $$$-fetoprotein showing the selective action with respect to cancer target-cells where the conjugated particles were bound by chemical bond and exhibiting resistance against proteases and other enzymes of biological fluids. Method of conjugate preparing involves interaction of protein or biologically active substance containing amino-group with succinylimidyl-trans-4-(N-maleiimidylmethyl)-cyclohexane-1-car-boxylate followed by cross-linking of the prepared derivative with biologically active substance or protein part of $$$-fetoprotein, respectively, by SH-groups. The latter can be incorporated additionally using 3-(2-pyridyldithio)-propionic acid succinimide ether. Variant: condensation of amino-groups of protein with aldehyde group of biologically active substance (parent or incorporated additionally after activation with periodate) followed by reduction of semiproduct with boron hydride. Pharmaceutical composition has effective amount of conjugate and carrier that can be useful for intravenous administration. Calichemycin is preferable active substance in conjugate. EFFECT: improved method of preparing, enhanced effectiveness of treatment.